以3小时输注方式给予210mg/m²紫杉醇的神经肌肉毒性。
Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.
作者信息
Kunitoh H, Saijo N, Furuse K, Noda K, Ogawa M
机构信息
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
出版信息
Br J Cancer. 1998 May;77(10):1686-8. doi: 10.1038/bjc.1998.278.
Abstract
We retrospectively analysed neuromuscular toxicity associated with paclitaxel 210 mg m(-2) given by 3-h infusion in 247 patients. The severity correlated significantly with total cumulative dose, but could not be predicted by the pretreatment clinical variables or by pharmacokinetic parameters. The toxicity tended to occur in early treatment cycles.
摘要
我们回顾性分析了247例接受3小时输注210mg/m²紫杉醇治疗的患者的神经肌肉毒性。严重程度与总累积剂量显著相关，但无法通过治疗前临床变量或药代动力学参数预测。毒性倾向于在治疗早期周期出现。
相似文献
1
Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.
Br J Cancer. 1998 May;77(10):1686-8. doi: 10.1038/bjc.1998.278.
2
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22.
3
Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Semin Oncol. 1996 Dec;23(6 Suppl 16):42-6.
4
Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Jpn J Cancer Res. 1995 Dec;86(12):1203-9. doi: 10.1111/j.1349-7006.1995.tb03316.x.
5
6
Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Semin Oncol. 1995 Dec;22(6 Suppl 15):29-33.
7
Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
Semin Oncol. 1996 Dec;23(6 Suppl 16):68-70.
8
Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Semin Oncol. 1995 Dec;22(6 Suppl 15):24-8.
9
Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
Int J Clin Oncol. 2003 Feb;8(1):45-8. doi: 10.1007/s101470300006.
10
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-40-S15-43.
引用本文的文献
1
Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management.
Curr Treat Options Oncol. 2025 Mar;26(3):187-196. doi: 10.1007/s11864-025-01302-y. Epub 2025 Feb 28.
2
Topical coapplication of hyaluronan with transdermal drug delivery enhancers attenuates inflammatory and neuropathic pain.
Pain. 2023 Dec 1;164(12):2653-2664. doi: 10.1097/j.pain.0000000000002993. Epub 2023 Jul 18.
3
Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment.
Support Care Cancer. 2023 Jun 3;31(6):372. doi: 10.1007/s00520-023-07852-x.
4
Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis.
Support Care Cancer. 2021 Dec;29(12):8059-8067. doi: 10.1007/s00520-021-06342-2. Epub 2021 Jul 6.
5
The challenge of preserving cardiorespiratory fitness in physically inactive patients with colon or breast cancer during adjuvant chemotherapy: a randomised feasibility study.
BMJ Open Sport Exerc Med. 2015 Oct 23;1(1):e000021. doi: 10.1136/bmjsem-2015-000021. eCollection 2015.
6
Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat.
Pain. 2014 Jun;155(6):1161-1167. doi: 10.1016/j.pain.2014.03.004. Epub 2014 Mar 15.
7
Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy.
Ann Neurol. 2011 Jul;70(1):101-9. doi: 10.1002/ana.22382.
8
Abnormal muscle afferent function in a model of Taxol chemotherapy-induced painful neuropathy.
J Neurophysiol. 2011 Jul;106(1):274-9. doi: 10.1152/jn.00141.2011. Epub 2011 May 11.
9
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
Br J Cancer. 2001 Jan;84(2):170-8. doi: 10.1054/bjoc.2000.1572.
本文引用的文献
1
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Clin Cancer Res. 1995 Jun;1(6):599-606.
2
Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Jpn J Cancer Res. 1995 Dec;86(12):1203-9. doi: 10.1111/j.1349-7006.1995.tb03316.x.
3
Theoretical and practical aspects of paclitaxel scheduling.
Ann Oncol. 1995 Nov;6(9):861-3. doi: 10.1093/oxfordjournals.annonc.a059349.
4
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
J Clin Oncol. 1994 Dec;12(12):2654-66. doi: 10.1200/JCO.1994.12.12.2654.
5
Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion.
Jpn J Cancer Res. 1994 Oct;85(10):1057-62. doi: 10.1111/j.1349-7006.1994.tb02906.x.
6
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Ann Neurol. 1994 Mar;35(3):304-11. doi: 10.1002/ana.410350310.
7
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
J Clin Oncol. 1995 Jan;13(1):180-90. doi: 10.1200/JCO.1995.13.1.180.
8
Paclitaxel-induced neuropathy.
Ann Oncol. 1995 May;6(5):489-94. doi: 10.1093/oxfordjournals.annonc.a059220.
9
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
J Clin Oncol. 1994 Feb;12(2):241-8. doi: 10.1200/JCO.1994.12.2.241.
10
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
J Clin Oncol. 1987 Aug;5(8):1232-9. doi: 10.1200/JCO.1987.5.8.1232.
Zotero 插件